반응식
[CH3:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]2[CH:13]=NN(C)C=2)=[C:6]([CH:11]=1)[C:7]([O:9][CH3:10])=[O:8].CC1C=CC(B2OC(C)(C)C(C)(C)O2)=C(C=1)C(OC)=O.[Cl:38][C:39]1[N:44]=C(Cl)C=[CH:41][N:40]=1>>[Cl:38][C:39]1[N:44]=[C:12]([C:5]2[CH:4]=[CH:3][C:2]([CH3:1])=[CH:11][C:6]=2[C:7]([O:9][CH3:10])=[O:8])[CH:13]=[CH:41][N:40]=1참가 물질
4
실험 절차
The title compound was synthesized following the same general protocol as described for methyl 5-methyl-2-(1-methyl-1H-pyrazol-4-yl)benzoate in Example A1, using methyl 5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and 2,4-dichloropyrimidine. ESI-MS (m/z): 263 [M+1]+.
출처 및 근거
- ORD 기록
- ord-5d81e4ba5f6343f09f530925509d1f00
- 출처 데이터셋
- uspto-grants-2016_09
- 특허 번호
- US09440982B2
연결된 노트
불러오는 중…